Effect of 5-fluorouracil on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats

European Journal of Pharmaceutical Sciences

Volumn 17, Issue 1-2, 2002, Pages 73-80

  Zhou, Qingyu ^a   Chan, Eli ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

5 Fluorouracil; Pharmacodynamics; Pharmacokinetics; Stereoselective drug interactions; Warfarin

Indexed keywords

ABSORPTION; BLOOD; COAGULATION; METABOLITES; PHARMACOKINETICS; PROTEINS;

ANTICOAGULANTS;

DRUG PRODUCTS;

FLUOROURACIL; WARFARIN;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; ENANTIOMER; HYPOPROTHROMBINEMIA; MALE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RACEMIC MIXTURE; RAT;

ANIMALS; ANTICOAGULANTS; AREA UNDER CURVE; DRUG INTERACTIONS; DRUG SYNERGISM; FLUOROURACIL; MALE; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; WARFARIN;

EID: 0036804638     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(02)00148-3     Document Type: Article

References (37)

1. Afsar A., Lee C., Riddick D.S. Modulation of the expression on constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil. Can. J. Physiol. Pharmacol. 74:1996;150-156.
2. Au J.L., Walker J.S., Rustum Y. Pharmacokinetic studies of 5-fluorouracil and 5′-deoxy-5-fluorouridine in rats. J. Pharmacol. Exp. Ther. 227:1983;174-180.
3. Banfield C., Rowland M. Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. J. Pharm. Sci. 73:1984;1392-1396.
4. Breckenridge A., Orme M., Wesseling H., Lewis R.J., Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin. Pharmacol. Ther. 15:1974;424-430.
5. Brown M.C. An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature. Chemotherapy. 45:1999;392-395.
6. Chan E., McLachlan A., O'Reilly R., Rowland M. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin. Pharmacol. Ther. 56:1994;286-294.
7. Chlebowski R.T., Gota C.H., Chan K.K., Weiner J.M., Block J.B., Bateman J.R. Clinical and pharmacokinetic effects of combined warfarin and 5-fluorouracil in advanced colon cancer. Cancer Res. 42:1982;4827-4830.
8. Curt G.A., Allegra R.L., Fine G.C., Yen G.C., Jolivet J., Chabner B.A. Fluoropyrimidines in cancer chemotherapy. Pinedo H.M., Chabner B.A., The EORTC Cancer Chemotherapy Annual. 1984;8-14 Elsevier, Oxford.
9. Diasio R.B., Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16:1989;215-237.
10. Donelli M.G., Franchi G., Rosso R. The effect of cytotoxic agents on drug metabolism. Eur. J. Cancer. 6:1970;125-126.
11. Donelli M.G., Garattini S. Drug metabolism after repeated treatments with cytotoxic agents. Eur. J. Cancer. 7:1971;361-364.
12. Fasco M.J., Piper L.J., Kaminsky L.S. Biochemical applications of a quantitative high-pressure liquid chromatographic assay of warfarin and its metabolites. J. Chromatogr. 131:1977;365-373.
13. Haaz M.C., Rivory L., Riche C., Vernillet L., Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res. 58:1998;468-472.
14. Hermodson M.A., Barker W.M., Link K.P. Studies on the 4-hydroxycoumarins. Synthesis of the metabolites and some other derivatives of warfarin. J. Med. Chem. 14:1971;167-169.
15. Inselmann G., Holzlohner U., Heidemann H.T. Effect of 5-fluorocytosine and 5-fluorouracil on human and rat hepatic cytochrome P450. Mycoses. 32:1989;638-643.
16. Kirsch W.M., Schulz D., Van Buskirk J.J., Young H.E. Effects of sodium warfarin and other carcinostatic agents on malignant cells: a study of drug synergy. J. Med. 5:1974;69-82.
17. Klubes P., Cerna I. Effects of 5-fluorouracil on drug-metabolizing enzymes in the rat. Cancer Res. 34:1974;927-931.
18. Kolesar J.M., Johnson C.L., Freeberg B.L., Berlin J.D., Schiller J.H. Warfarin-5-FU interaction: a consecutive case series. Pharmacotherapy. 19:1999;1445-1449.
19. Levine M.N., Bramwell V.H., Pritchard K.I., Norris B.D., Shepherd L.E., Abu-Zahra H., Findlay B., Warr D., Bowman D., Myles J., Arnold A., Vandenberg T., MacKenzie R., Robert J., Ottaway J., Burnell M., Williams C.K., Tu D. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 16:1998;2651-2658.
20. Lewis R.J., Trager W.F., Chan K.K., Breckenridge A., Orme M., Rowland M., Schary W. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J. Clin. Invest. 53:1974;1607-1617.
21. Malet-Martino M.-C., Martino R., Lopez A., Beteille J.-P., Bon M., Bernadou J., Armand J.-P. New approach to metabolism of 5′-deoxy-5-fluorouridine in humans with fluorine NMR. Cancer Chemother. Pharmacol. 13:1984;31-35.
22. McLeod H.L., Sludden J., Hardy S.C., Lock R.E., Hawksworth G.M., Cassidy J. Autoregulation of 5-fluorouracil metabolism. Eur. J. Cancer. 34:1998;1623-1627.
23. Naguib F.N., el Kouni M.H., Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res. 45:1985;5405-5412.
24. 13C]warfarin pseudoracemates in man. J. Clin. Invest. 65:1980;746-753.
25. Pohl L.R., Bales R., Trager W.F. Warfarin: stereochemical aspects of its metabolism in vivo in the rat. Res. Commun. Chem. Pathol. Pharmacol. 15:1976;233-256.
26. Porter R.S., Sawyer W.T., Lowenthal D.T. Warfarin. Evans W.E., Schentag J.J., Jusko W.J., Harrison H., Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 1986;1057-1104 Applied Therapeutics Inc, Spokane, WA.
27. Rettie A.E., Eddy A.C., Heimark L.D., Gibaldi M., Trager W.F. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug. Metab. Dispos. 17:1989;265-270.
28. Rettie A.E., Korzekwa K.R., Kunze K.L., Lawrence R.F., Eddy A.C., Aoyama T., Gelboin H.V., Gonzalez F.J., Trager W.F. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5:1992;54-59.
29. Rizzo J.D., Davis P.J. Microbial models of mammalian metabolism: conversion of warfarin to 4′-hydroxywarfarin using Cunninghamella bainieri. J. Pharm. Sci. 78:1989;183-189.
30. Ryan J.J., Ketcham A.S., Wexleer H. Reduced incidence of spontaneous metastases with long-term coumadin therapy. Ann. Surg. 168:1968;163-168.
31. Scarfe M.A., Israel M.K. Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann. Pharmacother. 28:1994;464-467.
32. Stupans I., Richards D.A., McClure M.T. Effects of 5-fluorouracil treatment on rat liver microsomal enzymes. Xenobiotica. 25:1995;1-8.
33. Trager W.F., Lewis R.J., Garland W.A. Mass spectral analysis in the identification of human metabolites of warfarin. J. Med. Chem. 13:1970;1196-1204.
34. Umezawa T., Kiba T., Numata K., Saito T., Nakaoka M., Shintani S., Sekihara H. Comparisons of the pharmacokinetics and the leukopenia and thrombocytopenia grade after administration of irinotecan and 5-fluorouracil in combination to rats. Anticancer Res. 20:2000;4235-4242.
35. Yoshisue K., Nagayama S., Shindo T., Kawaguchi Y. Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats. J. Pharmacol. Exp. Ther. 297:2001;1166-1175.
36. 10. J. Pharmacol. Toxicol. Methods. 40:1998;191-199.
37. Zhou S., Chan E. Effect of ubidecarenone on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats. Drug Metab. Drug Interact. 18:2001;99-122.